Dexamethasone Elixir
NDC Package 62135-114-37

11-digit billing NDC: 62135011437 · Billing unit: ML · 237 ML per package

Package Information

Dexamethasone elixirs is allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:        Seasonal or perennial allergic rhinitis        Bronchial asthma        Contact dermatitis        Atopic dermatitis        Serum sickness        Drug hypersensitivity reactions Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of:        Systemic lupus erythematosus        Acute rheumatic carditis Dermatologic Diseases        Pemphigus        Bullous dermatitis herpetiformis        Severe erythema multiforme (Stevens-Johnson syndrome)        Exfoliative dermatitis        Mycosis fungoides        Severe psoriasis        Severe seborrheic dermatitis Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). This formulation utilizes a elixir delivery system. Marketed by Chartwell Rx, Llc, this product is identified by NDC 62135-114 and is authorized under FDA application ANDA091188.

Identification & Billing

NDC Package Code
62135-114-37
Package Description
237 mL in 1 BOTTLE
Product Code
11-Digit Billing Format
62135011437
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
237 ML
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Dexamethasone
Non-Proprietary Name
Dexamethasone
Substance Name
Dexamethasone
Dosage Form
Elixir - A clear, pleasantly flavored, sweetened hydroalcoholic liquid containing dissolved medicinal agents; it is intended for oral use.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:        Seasonal or perennial allergic rhinitis        Bronchial asthma        Contact dermatitis        Atopic dermatitis        Serum sickness        Drug hypersensitivity reactions Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of:        Systemic lupus erythematosus        Acute rheumatic carditis Dermatologic Diseases        Pemphigus        Bullous dermatitis herpetiformis        Severe erythema multiforme (Stevens-Johnson syndrome)        Exfoliative dermatitis        Mycosis fungoides        Severe psoriasis        Severe seborrheic dermatitis Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).        Congenital adrenal hyperplasia        Nonsuppurative thyroiditis        Hypercalcemia associated with cancer Gastrointestinal Diseases To tide the patient over a critical period of the disease in:        Ulcerative colitis        Regional enteritis Hematologic Disorders        Idiopathic thrombocytopenic purpura in adults        Secondary thrombocytopenia in adults        Acquired (autoimmune) hemolytic anemia        Erythroblastopenia (RBC anemia)        Congenital (erythroid) hypoplastic anemia Miscellaneous Diagnostic testing of adrenocortical hyperfunction Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy        Trichinosis with neurologic or myocardial involvement Neoplastic Diseases For palliative management of:        Leukemia and lymphomas in adults        Acute leukemia of childhood Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as:        Allergic conjunctivitis        Keratitis        Allergic corneal marginal ulcers        Herpes zoster ophthalmicus        Iritis and iridocyclitis        Chorioretinitis        Anterior segment inflammation        Diffuse posterior uveitis and choroiditis        Optic neuritis        Sympathetic ophthalmia Respiratory Diseases        Symptomatic sarcoidosis        Loeffler's syndrome not manageable by other means        Berylliosis        Fulminating or disseminated pulmonary tuberculosis when used concurrently with        appropriate antituberculous chemotherapy        Aspiration pneumonitis Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:        Psoriatic arthritis        Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require        low-dose maintenance therapy)        Ankylosing spondylitis        Acute and subacute bursitis        Acute nonspecific tenosynovitis        Acute gouty arthritis        Post-traumatic osteoarthritis        Synovitis of osteoarthritis        Epicondylitis

Regulatory & Marketing

Labeler Name
Chartwell Rx, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA091188
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
05-11-2011
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

Source: PDAC
DEXAMETHASONE, ORAL, 0.25 MG
HCPCS Dosage 0.25 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 62135-114-37 identifies a specific commercial package of 237 ml in 1 bottle of Dexamethasone, a human prescription drug labeled by Chartwell Rx, Llc. This elixir is formulated for oral use and contains dexamethasone as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Chartwell Rx, Llc on May 11, 2011. The current certification is valid through December 31, 2026.

How is this Chartwell Rx, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 62135011437. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 237 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
62135-114-37
11-Digit CMS (5-4-2)
62135-0114-37

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.